Lucentis (ranibizumab) has now been cleared to treat patients for visual impairment due to CNV associated with causes other than neovascular age-related macular degeneration (nAMD) or secondary to
The Competition and Markets Authority (CMA) fined Pfizer £84.2m and Flynn Pharma £5.2m after they increased prices by as much as 2,600% in September 2012. Due to the price increases, the
Results from the first randomised Phase III data showed that Tagrisso reduced the risk of lung cancer progression by 70% compared to chemotherapy and improved progression-free survival (PFS)
The company submitted a new drug application (NDA) to the US Food and Drug Administration and a marketing authorisation application to the European Medicines Agency. Semaglutide works by stimulating insulin
Bosulif is an oral, once-daily, tyrosine kinase inhibitor, which inhibits the Bcr-Abl kinase that promotes CML. The BFORE study met its primary endpoint of major molecular response (MMR)
The company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI 100/62.5/25 mcg). The company submitted its MAA in the US several weeks
Jardiance can now be used to reduce the risk of cardiovascular death in adult patients with type 2 diabetes (T2D) mellitus and cardiovascular disease (CVD). The agency’s decision
The partnership will identify and develop bicyclic peptides, Bicycles, a novel class of small molecule medicines designed to overcome several limitations of existing drug modalities. The deal tasks Bicycle with identifying bicyclic peptides
The collaboration integrates cognitive computing capabilities of IBM Watson with Pfizer’s scientific know how to help scientists generate meaningful insights. Pfizer will be the first company to use
The acquisition is expected to expand the UK based Heptares’ intellectual assets and platform for structure-based drug design and development centred on G protein-coupled receptors (GPCRs). Considered to
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.